Image

Global Bioidentical Hormones Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220
  • Healthcare
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Bioidentical Hormones Market, By Type (Estrogens, Progesterone, Testosterone, Combined Hormones, Others), Product Type (Tablets and Capsules, Creams and Gels, Injectable, Patches and Implants, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospital, Gynaecology Clinics, Academic and Research, Others) – Industry Trends and Forecast to 2029

Bioidentical Hormones Market

Market Analysis and Size

In today’s fast pacing and stressful, experiencing hormonal imbalance is normal especially in women. With various kinds of hormonal changes, the female body develops diseases and abnormalities which is worsened by ageing. Hormonal imbalance invites problems such as weight gain, memory decline, fatigue, and muscle loss.

  • Data Bridge Market Research analyses that the bioidentical hormones market is expected to undergo a CAGR of 6.61% during the forecast period of 2022 to 2029. This indicates that the market value, which was USD 3.35 billion in 2021, would rocket up to USD 12.02 billion by 2029. “Estrogens” dominates the type segment of the bioidentical hormones market owing to the increase in number of research studies related to estrogen, rise in obesity and related health issues and advancements in healthcare technologies. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Bioidentical hormones are manmade hormones which are used to treat low or out of balance hormonal levels. Bioidentical hormones are similar to the hormones that are naturally produced in the body of both men and women. Bioidentical hormones are used to treat the hormonal imbalance and its effects on and in the body. Normally, hormonal imbalance in men is experienced after 40 years of age.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Billion, Pricing in USD

Segments Covered

Type (Estrogens, Progesterone, Testosterone, Combined Hormones, Others), Product Type (Tablets and Capsules, Creams and Gels, Injectable, Patches and Implants, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospital, Gynaecology Clinics, Academic and Research, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

SottoPelle (US), Novartis AG (Switzerland), Orion Pharma AB (Sweden), Full Life Wellness Center (US), BioTE Medical, LLC (US), Merck KGaA (Germany), Pfizer Inc. (US), TherapeuticsMD, Inc. (US), Papillon Medical (Canda), United Pharmacy (US), Noven Pharmaceuticals, Inc. (US), GEA Group Aktiengesellschaft (Germany), Novo Nordisk A/S (Denmark), GeneScience Pharmaceuticals Co., Ltd. (China), Actiza Pharmaceutical Private Limited (India), Defy Medical (US), Neuva Aesthetics (US), ZRT Laboratory (US), Bayer AG (Germany) and Allergan (Ireland)

Bioidentical Hormones Market Dynamics

Drivers

  • The rise in the prevalence of hormonal deficiency

Surging prevalence of hormonal deficiency especially in women all around the globe owing to various internal and external factors is one of the major factors responsible for fostering growth of the market. Rising patient pool especially in the developing economies is carving the way for the growth of the market.

  • Research and development proficiencies

Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the medical instruments and devices will further create lucrative market growth opportunities. Research and development proficiencies have led to the advancements in the medical technology and have improved the quality of healthcare facilities.  Increasing number of screening tests for research proficiencies has further widened the scope of growth.

  • Government investments on healthcare infrastructure

The increase in the funding by the federal government is set to drive the growth of the market. Moreover, growth and expansion of healthcare industry being driven by both public and private players especially in the developing economies will create lucrative personal health devices market growth opportunities. Also, growing acceptance of bioidentical hormones replacement therapy by the governmental healthcare facilities is also bolstering the market growth rate.

Additionally, surge in the personal disposable income level, introduction of technologically driven product in hospitals and increasing investment for the development of advanced and rise in focus on women health care and treatment of hormonal imbalances, positively affect the market growth rate.

Opportunities

Furthermore, upsurge in the public-private funding for target research activities, increasing need for improvised healthcare services owing to imbalance between health workforce and patients and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2022 to 2029. Additionally, surging number of strategic collaborations, rising lifestyle changes, increased stress and work pressure, irregular eating habits, and lack of exercise, growing number of hospitals and laboratories, rising geriatric population base, rising number of cross-industry partnerships and collaborations and increasing per capita expenditure on health care will further expand the market's growth rate in the future. 

Restraints/Challenges

On the other hand, high cost associated with the research and development proficiencies, safety issues related to the use of compound bioidentical hormones and difficulties related with the medical procedures are expected to obstruct market growth. Also, lack of favourable reimbursement scenario and technology penetration in the developing economies, various side effects such as weight loss and blurred vision, high risk of heart attack and breast cancer and lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2022-2029.

This bioidentical hormones market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bioidentical hormones market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Covid-19 Impact on Bioidentical Hormones Market

Covid-19 has had a negative impact on the market. Reduced focus on non-essential medical procedures and postponement of healthcare procedures has put a dent on the market growth rate. Moreover, halt on the number of research and development proficiencies further restricted the scope of growth in the pandemic phase.  

Recent Developments

  • In August 2020, the US FDA approved Sogroya (somapacitan), a human growth hormone (HGH) therapy for adult patients with growth hormone deficiency, which is indicated to be taken once a week by injection under the skin.
  • In December 2020, the US FDA approved Thyquidity (levothyroxine) oral solution, of VistaPharm, for replacement therapy of primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital.
  • In December 2020, the US FDA approved the Myovant Sciences' Orgovyx (relugolix), which is an orally administered treatment.
  • In August 2020, Bayer AG announced the acquisition of KanDy Therapeutics Inc., which aids in the expansion of Bayer's women's drug pipeline by adding KanDy's menopause drug to its portfolio.

Global Bioidentical Hormones Market Scope

The bioidentical hormones market is segmented on the basis of type, product type, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Estrogens
  • Progesterone
  • Testosterone
  • Combined Hormones
  • Others

On the basis of type, the bioidentical hormones market is segmented into estrogens, progesterone, testosterone, combined hormones and others.

Product type

  • Tablets and Capsules
  • Creams and Gels
  • Injectable
  • Patches and Implants
  • Others

Based on product type, the bioidentical hormones market is segmented into tablets and capsules, creams and gels, injectable, patches and implants and others. 

Distribution channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

On the basis of distribution channel, the bioidentical hormones market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.

End user

  • Hospital
  • Gynaecology Clinics
  • Academic and Research
  • Others

The end user segment of the bioidentical hormones market is segmented into hospital, gynaecology clinics, academic and research and others.

Bioidentical Hormones Market Regional Analysis/Insights

The bioidentical hormones market is analysed and market size insights and trends are provided by country, type, product type, distribution channel and end user as referenced above.

The countries covered in the bioidentical hormones market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the bioidentical hormones market because of the strong base of healthcare facilities, availability of reimbursements, rising geriatric population, high healthcare spending combined with the onset of COVID-19 pandemic and rising number of research activities in this region.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, ever-rising geriatric population base and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The bioidentical hormones market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for bioidentical hormones market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the bioidentical hormones market. The data is available for historic period 2010-2020.

Competitive Landscape and Bioidentical Hormones Market Share Analysis

The bioidentical hormones market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bioidentical hormones market.

Some of the major players operating in the bioidentical hormones market are SottoPelle (US), Novartis AG (Switzerland), Orion Pharma AB (Sweden), Full Life Wellness Center (US), BioTE Medical, LLC (US), Merck KGaA (Germany), Pfizer Inc. (US), TherapeuticsMD, Inc. (US), Papillon Medical (Canda), United Pharmacy (US), Noven Pharmaceuticals, Inc. (US), GEA Group Aktiengesellschaft (Germany), Novo Nordisk A/S (Denmark), GeneScience Pharmaceuticals Co., Ltd. (China), Actiza Pharmaceutical Private Limited (India), Defy Medical (US), Neuva Aesthetics (US), ZRT Laboratory (US), Bayer AG (Germany) and Allergan (Ireland) among others.


SKU-
Why Choose Us


Frequently Asked Questions

Bioidentical Hormones Market value to reach USD 12.02 billion by forecast 2029.
The Bioidentical Hormones Market is Projected to Grow at a CAGR of 6.61%.
Factors such as the rapid increase in geriatric population, rise in screening for hormonal deficiency, increase in the patient pool and increasing personal disposable income are the major growth driving factors.
The Major Players Operating in the Bioidentical Hormones Market are SottoPelle (US), Novartis AG (Switzerland), Orion Pharma AB (Sweden), Full Life Wellness Center (US), BioTE Medical, LLC (US), Merck KGaA (Germany), Pfizer Inc. (US), Defy Medical (US), Neuva Aesthetics (US), ZRT Laboratory (US), Bayer AG (Germany) and Allergan (Ireland) are the major companies operating in this region.
The Major Countries Covered in Bioidentical Hormones Market market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.